Expression of survivin, a member of the inhibitor of apoptosis protein family, is elevated in human cancers and considered as a new therapeutic target. Mechanism upregulating survivin expression in tumour cells is poorly understood. In this study, we show that breast cancer patients harbouring a polymorphism G235A in the survivin promoter present a higher level of survivin expression. This polymorphism creates a binding site for the transcription factor GATA-1 inducing a second GATA-1-binding site in survivin promoter. At the mRNA level, GATA-1 was present in breast carcinomas and adjacent normal tissues, whereas the protein was only detected in carcinomas by western blot and immunohistochemistry. Transfection of wild-type and different constitutively active GATA-1 mutants (serine 26, 178 or 310) showed that only phospho-serine 26 GATA-1 was able to increase survivin expression. This increase was higher in G235A than in G235G cell lines. Phospho-serine 26 GATA-1 bound directly survivin promoter, with a stronger interaction in G235A than in G235G polymorphism indicating that both GATA-1-binding sites are functional. These data identify GATA-1 as a key feature in tumour aggressiveness by enhancing survivin expression and delineate its targeting as a possible new therapeutic strategy in breast carcinomas.
Introduction
Survivin (encoded by BIRC5) is the smallest inhibitor of apoptosis protein. It is strongly expressed in fetal tissues whereas its expression in adult ones is limited to specific tissues including thymus, placenta, spleen, intestinal crypt epithelium and bone marrow (Ambrosini et al., 1997; Altieri and Marchisio, 1999; Li, 2003) . The transcript is also sharply differentially expressed in human cancers (Ambrosini et al., 1997; Li, 2003) , including breast cancer (Nasu et al., 2002; O'Driscoll et al., 2003; Ryan et al., 2005; Ve´gran et al., 2005 Ve´gran et al., , 2007 Boidot et al., 2009) . Survivin is encoded by a complex gene, and its expression is finely regulated by transcriptional and post-transcriptional mechanisms. This protein is an essential regulator of cell division (Connell et al., 2008) , a modulator of apoptotic and nonapoptotic cell death and a stress response factor ensuring continued cell proliferation and cell survival in the face of unfavourable milieus (Altieri, 2005) . Survivin antagonizes apoptosis (Obexer et al., 2009) , promotes tumour-associated angiogenesis (Zhen et al., 2007) and acts as a resistance factor to various anticancer therapies (Wu et al., 2008) . Although there are disparate and seemingly distant fields of investigation, only a holistic understanding of survivin function across the different areas can unlock the potential of the survivin networks for novel cancer therapeutics. These roles of survivin offer unique prospects for drug discovery and clinical trials targeting this protein are now underway (Altieri, 2008) .
The survivin gene promoter possesses a canonical CpG island and numerous Sp1 sites but no TATA box. The survivin proximal promoter contains G 1 transcriptional repressor element CDE (Cell cycle-Dependent Element) and CHR (Cell-cycle gene Homology Region). These CDE/CHR regions increase the activity of survivin promoter during G2/M, whereas the deletion of CDE/CHR motifs suppresses the cell-cycle-dependent expression of survivin and leads to an expression in all phases of the cell cycle (Li et al., 1998; Li and Altieri, 1999) . Nevertheless, areas outside of the core promoter of survivin are involved in both its constitutive and cell cycle-dependent expression (Xia and Altieri, 2006) .
Three single nucleotide polymorphisms (SNP) have been previously analysed in the survivin promoter, at À241, À235 and À31 and one of them (C31G), located in the CDE/CHR repressor element, was reported to correlate with increased survivin expression (Xu et al., 2004) . However, we failed to confirm this finding in breast carcinomas (Boidot et al., 2008) . This study focuses on the SNP G235A, as this polymorphism creates an alternative binding site for the transcriptional factor GATA-1.
Results

Survivin overexpression in breast carcinomas
By using quantitative RT-PCR to measure survivin mRNA expression in 158 breast carcinomas and 56 adjacent normal tissues, we observed that survivin expression was significantly higher (Po0.0001) in carcinomas than in normal tissues ( Figure 1a) . We also analysed the SNP at À31, À235 and À241 of the survivin promoter in 121 breast carcinomas. The results confirmed the lack of correlation between SNP at À31 and survivin expression in breast carcinoma (Boidot et al., 2008) . Details about clinical parameter distribution between G/G and G/A subsets were presented in Supplementary Table S2 . We did not identify any correlation between SNP at -241 and survivin expression in breast carcinoma. In contrast, G235A SNP was strongly associated with an increased global survivin mRNA level in breast carcinomas (P ¼ 0.0062) (Figure 1b ). Correlation was also made with each transcript. Although no statistically significant correlations, expression of all survivin variants were higher with G/A polymorphism than G/G, and survivin expression still significantly (P ¼ 0.0384) increased with G/A polymorphism (Supplementary Figure S2 ).
The G235A polymorphism creates a GATA-1-binding site in the survivin promoter We then analysed the consequences of G235A polymorphism in survivin promoter in silico, using the TFSEARCH website (http://www.cbrc.jp/research/db/ TFSEARCH.html). This search indicated that the G235A SNP created a consensus GATA-1-binding site: CTAGATGTGG. This analysis also detected a constitutive GATA-1-binding site spreading from À373 to À364 of the survivin promoter: CGTGATGGCC. Quantitative RT-PCR analysis of 158 breast carcinomas and 56 adjacent normal tissues detected GATA-1 mRNA in both normal and cancer tissues without any significant differences (Figure 2a ). In parallel, we compared expression of survivin and GATA-1 at the mRNA level on 158 carcinomas. The correlation was not statistically significant (r ¼ 0.124, P ¼ 0.1218). Immunoblot analysis of the GATA-1 protein in 10 couples of carcinomas and their adjacent normal tissues easily detected GATA-1 protein in 9 of 10 (90%) carcinomas, with different intensity levels, but failed to identify GATA-1 in any of the corresponding normal tissues (Figure 2b ). Among these 10 couples, nine were G/G and one was G/A (patient 8). This observation was confirmed by immunohistochemistry on paraffinembedded tissues. Indeed, benign breast tissue (patient 1) did not present any nuclear staining of GATA-1 (Figure 2c ) whereas malignant carcinoma (patient 1) harboured strong nuclear staining with anti-GATA-1 antibody (Figure 2d ). The malignant carcinoma of patient 10 was negative for GATA-1 detection also by immunohistochemistry (Supplementary Figure S3) . No red blood cells and no differences in angiogenesis between the different tumours analysed by immunohistochemistry (anti-CD31) were observed (data not shown).
Finally, we compared GATA-1 protein level and overall survivin mRNA expression to determine whether survivin gene expression may be prejudiced by GATA-1 amount in patients harbouring only GATA-1 binding sequence at À373. The data indicated that the protein expression of GATA-1 was associated with overall survivin expression in breast carcinomas (Figure 2e ).
GATA-1 needs to be phosphorylated on 26-serine residue to enhance survivin expression We determined by direct sequencing the polymorphisms of survivin promoter in 13 cell lines. Only CCRF-CEM cells harboured a G/A polymorphism at À235, whereas breast cell lines had a G/G sequence (Supplementary Table S3 ). The polymorphisms were confirmed by multiple independent PCR-sequencing procedures. As GATA-1 expression has never been determined in breast tumour cell lines, we first analysed, by quantitative RT-PCR and western blot, the GATA-1 expression in GATA-1-binding sites in survivin promoter R Boidot et al CCRF-CEM and three breast cell lines (MDA-MB-231, MCF-7 and HBL100). CCRF-CEM is a leukaemia cell line and it is expected to express GATA-1. Surprisingly, MDA-MB-231 expressed GATA-1 at the mRNA and protein levels. Chromatin immunoprecipitation (ChIP) experiments showed a large band with CCRF-CEM, whereas no amplification was observed with MCF-7, HBL100, IgG or agarose beads (Supplementary Figure  S4) . Interestingly, a weak band was present with MDA-MB-231, translating that the constitutive GATA-1-binding site could be used in survivin promoter. These results were in agreement with those observed in breast carcinomas ( Figure 2e ). However, the presence of G/A polymorphism at À235 induced a stronger signal. When we normalized the signal obtained with the ChIP analysis by the amount of GATA-1 protein (obtained by western blot quantification), the ratios were equal to 1333 for CCRF-CEM and 264 for MDA-MB-231, suggesting that the presence of the alternative GATA-1-binding site induces a 5-fold increase of the GATA-1 binding on the survivin promoter. GATA-1 was shown to be activated by phosphorylation on various serine residues (Crossley and Orkin, 1994; Towatari et al., 2004; Kadri et al., 2005) . GATA-1 has a role in cell survival by regulating promoters of several anti-apoptotic genes such as nitric-oxide synthase, antioxidant enzymes and anti-apoptotic proteins such as Bcl-X L (Yu et al., 2005) . We generated the three principal constitutively active forms of GATA-1 by replacement of Ser26, 178 and 310 with glutamate residues. The wild-type as well as the constitutively active mutants of GATA-1 were introduced in YFPcontaining vectors. These constructs were transiently expressed in the CCRF-CEM cells in which the survivin promoter shows the G235A SNP. The empty vector was used as a negative control. Transfection efficacy was confirmed by measurement of GATA-1 mRNA expression ( Figure 3a ) and the protein was detected by immunoblot experiments using an anti-GFP antibody ( Figure 3b ). The quantification was normalized to the bactin signal. Our results indicated that only the GATA-1 construct in which Ser26 has been replaced by a Glu residue increased significantly (P ¼ 0.0161) the survivin mRNA expression as compared with control YFP vector ( Figure 3c ). All other forms of GATA-1 had no effect on survivin mRNA expression compared to YFP tranfected cells.
As GATA-1 was also expressed in breast carcinomas in which the G235A SNP was not found, we tested the consequences of GATA-1 overexpression on survivin gene expression in MCF-7 cells that does not show this polymorphism (Figures 4a and b) . The obtained results were similar to those observed in CCRF-CEM cells, that is, only the GATA-1 construct in which Ser26 had been replaced by Glu increased survivin mRNA expression (P ¼ 0.0365) (Figure 4c ). However, the increase in survivin mRNA expression induced by overexpression of Ser26Glu GATA-1-YFP was higher in the presence of the G235A SNP (P ¼ 0.0129). The appearance of an alternative GATA-1 binding site at À235 increases the GATA-1-induced expression of survivin gene. In normal tissues, no GATA-1 protein was detected and survivin mRNA level was very low. In tumours, GATA-1 protein was detected with a weak or a strong protein expression and survivin mRNA expression was more important than in normal tissues with no GATA-1 protein.
GATA-1-binding sites in survivin promoter R Boidot et al
Currently, no anti-phospho-serine 26-GATA-1 antibody is available; as a consequence we were unable to detect the level of phosphor-serine 26-GATA-1 protein in the breast carcinomas.
GATA-1 strongly binds the survivin promoter in the presence of A polymorphism at À235 To determine whether GATA-1 could bind the survivin promoter in vivo, we performed ChIP experiments on MCF-7 (G/G) and CCRF-CEM (G/A) cell lines after transient transfection with vectors encoding YFP, wildtype GATA-1-YFP and Ser26Glu GATA-1-YFP. As shown in Figure 5a , only Ser26Glu GATA-1-YFP was able to bind survivin promoter in CCRF-CEM and MCF-7 cells. Interestingly, the band obtained with CCRF-CEM, whose survivin promoter contains two putative GATA-1 binding sites instead of one, was larger than the band amplified with MCF-7 (Figure 5b ). These results strongly suggest that Ser26Glu GATA-1-YFP can bind both GATA-1 À235 and À373 binding sites on the survivin promoter. As it was impossible to cut the survivin promoter by restriction enzymes between the two sites before ChIP experiment, both GATA-1 binding sites were studied together.
Finally, we checked whether GATA-1 in breast cancer could be a therapeutic target. We transfected a control siRNA or a GATA-1 siRNA into CCRF-CEM cells, that highly express GATA-1 to analyse the efficiency. The obtained extinction of GATA-1 was about 70% (Supplementary Figure S5) . As breast cancer cells express GATA-1 less than CCRF-CEM, we transfected the control siRNA and the GATA-1 siRNA into MDA-MB-231. As shown in Figure 5c , the targeting of GATA-1 in MDA-MB-231 cells induced a break in the growth curve, showing that GATA-1 extinction influence breast cancer cell growth.
Discussion
Survivin gene is overexpressed in most common types of human cancers. This has been explained by a variety of GATA-1-binding sites in survivin promoter R Boidot et al mechanisms (Altieri, 2003) . Several SNP were identified in the survivin gene promoter, including one located at CDE/ CHR repressor elements that appears to be a common mutation in cancer compared with normal cells. It changes the binding motif of the CDE/CHR repressor and correlates with increased survivin expression at both mRNA and protein levels (Xu et al., 2004 ). Whereas we did not observe any effect of an SNP at À31 on survivin expression in breast carcinomas (Boidot et al., 2008) , we showed here that an SNP at À235 strongly correlates to survivin expression level. The G to A change at À235 (corresponding to the G/A polymorphism at this site) creates a GATA-1-binding element in the survivin promoter. Interestingly, this GATA-1 promoter generated by an SNP is associated with a constitutive GATA-1 binding site spreading from À373 to À364 in the survivin promoter. SNP inducing the appearance of a new GATA-1 binding site has been observed in erythroid cells of a-thalassemia patients, more specifically in the a-globin promoter, leading to a-globin protein overexpression (De Gobbi et al., 2006) . Although the transcription factor GATA-1 is considered to be specific of erythroid and megakaryocytic cells, a constitutively bound GATA-1 was identified in the DNA of the A549 lung tumour cell line (Richter et al., 2003) , indicating that GATA-1 can be expressed in non hematopoietic cells. The prostate-specific antigen is a potential target gene for GATA transcription factors, but GATA-2 and -3 are the predominant GATA family members expressed in the prostate tissue (Perez-Stable et al., 2000) . Here, we show the presence of the corresponding mRNA without detection of the protein in normal breast tissue, which could indicate a degradation of the transcription factor in normal conditions. In transformed cells, both the gene and the protein are upregulated. Another gene whose expression is increased in breast cancer cells is aromatase P450 (P450arom) whose promoter includes two consensus GATA sites (Sebastian et al., 2002) .
Why GATA-1 is not expressed in breast normal cells when the protein accumulates in tumour cells is unclear. GATA-1 cleavage by caspase-8 was proposed to have an important role in the negative control of erythropoiesis (De Maria et al., 1999) ), whereas GATA-1 was protected from differentiation-associated activation of caspase-3 by interaction with HSP70 (Ribeil et al., 2007) . HSP70 expression is increased in breast carcinomas (Ciocca and Calderwood, 2005) and could protect GATA-1 from degradation in transformed cells when caspases are activated. However, other protective mechanisms may operate as caspase activation in breast carcinomas leads to cell death rather than differentiation.
In erythroid cells exposed to erythropoietin, GATA-1 is the final effector of signalling pathways involving phosphatidylinositol-3-phosphate/protein kinase, B-Akt (Zhao et al., 2006) , which phosphorylates the transcription factor on serine 310 (Kadri et al., 2005) , and mitogen-activated protein kinase (MAPK) cascade, which phosphorylates GATA-1 on serine 26 and 178 (Towatari et al., 2004; Yu et al., 2005) . Interestingly, the anti-apoptotic function of GATA-1 has been found to be strongly dependent upon its phosphorylation at the serine 26 position (Yu et al., 2005) . Here, we show that GATA-1 stimulates survivin gene transcription when phosphorylated on serine 26, indicating an upstream role for MAPK pathway in survivin overexpression in breast cancer cells.
GATA-1 stimulates the transcription of numerous genes that include the erythropoietin receptor (EpoR) gene (Chiba et al., 1991; Zon et al., 1991) . The stimulation of EpoR by Epo binding increases GATA-1 gene expression is a positive feedback loop (Chiba , 1991) and induces GATA-1 phosphorylation and activation (Zhao et al., 2000) . In addition, survivin was shown to be required for red blood cell formation (Leung et al., 2007) . These observations have two consequences. First, it may be interesting to determine whether the À235 polymorphism of survivin promoter affects erythropoiesis and favours erythrocemia. Secondly, as Epo is administered to breast cancer patients to prevent chemotherapy-induced anaemia during cancer treatment, it may be useful to check whether this treatment has no negative impact on the therapeutic control of breast cancer (Phillips et al., 2007) by increasing GATA-1 expression and downstream resistance genes such as survivin and bcl-xL.
GATA-1-binding sites in survivin promoter
In individuals harbouring G/G genotype at -235, survivin basal expression is regulated by GATA-1 by using À373 binding site. GATA-1 had a synergistic effect with Sp1 and EKLF (Gregory et al., 1996) . In the survivin promoter, polymorphism at À235 is closed to a Sp1 site. We could speculate that the G235A SNP could favour a synergistic effect of GATA-1 and Sp1 to promote survivin expression (Figure 6 ).
In conclusion, we show that polymorphism in the survivin promoter creates an 'alternative' binding site for the transcription factor GATA-1, which can enhance the expression of the protein in breast carcinomas. The G/A polymorphism at À235 in the survivin promoter may constitute a marker of breast tumour aggressiveness. Targeting survivin or GATA-1 in tumours could be an efficient therapeutic strategy in breast carcinomas, especially those harbouring such a polymorphism.
Materials and methods
Cell lines and RNA, DNA, proteins extraction Human breast cell lines, MCF-7, HBL100, MCF-10A, MDA-MB-231, MDA-MB-157 and Hs578T were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA). Pulmonary (A549), ovary (IGROV) and leukaemia (HL60, RPMI, K562 and CCRF-CEM) cell lines were supplied by Oncodesign (Dijon, France); cervical tumour cell line (HeLa) was purchased from ATCC. All cell lines were cultured in RPMI 1640 medium supplemented with 10% Fetal Bovine Serum. RNA and DNA extraction was performed by using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Total protein extraction was carried out by addition of lyses buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Sodium pyrophosphate, 1 mM b-Glycerophosphate, 1 mM Na 3 VO 4 , 1mg/ml Leupeptin, 1 mM PMSF added immediately before use) on cell monolayer for 5 min on ice. Afterwards, the lysates were harvested and sonicated.
Patients, samples and DNA/RNA extraction We studied a series of 158 patients with primary breast carcinomas. Corresponded adjacent normal tissues were also obtained for 56 patients. This study was done with the approval of the local boards governing research on human subjects. DNA and total RNA were extracted as described previously (Ve´gran et al., 2007) . After extraction by TRIzol reagent, protein pellets were kept and used for GATA-1 western blotting on 10 breast carcinomas and their adjacent normal tissues.
Western blot analysis
Western blots were performed as described previously (Ve´gran et al., 2007) with following primary antibodies (Abcam, Cambridge, UK): b-actin 1:25 000, GFP 1:50 000, GATA-1 1:5000 or Survivin 1:5000.
Immunohistochemistry of paraffin-embedded tissues
Formalin-fixed tissues were embedded into paraffin. Fivemicrometer sections were disposed on glass slides. Sections were deparaffinized by two neoclear bathes (Merck, Whitehouse Station, NJ, USA) of 2 min, and dehydrated by 2 min bathes of 100, 90, 70 and 50% ethanol and a final 2 min bath of water. Antigen retrieval step was performed with Dako Target retrieval solution (Dako, Glostrup, Denmark) by incubating sections during 30 min at 95-99 1C without boiling. Then, the jar containing sections and Dako Target retrieval solution was removed from the water bath and incubated 20 min at room temperature. After two 5 min PBS washes, peroxidases were inhibited by incubation for less than 5 min with Peroxydaseblocking reagent (Dako). After two 5-min PBS washes, tissues were permeabilized with Triton 0.3% for 10 min, and blocked with PBS Tween 0.1%/BSA 5% for 1 h. Afterwards, tissue G/G at -235 G/A at -235
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Survivin promoter -373 -232 -373 -232 -239 Figure 6 A hypothetical model for the regulation of survivin expression by GATA-1. In the presence of G/G SNP at À235, GATA-1 induces survivin basal expression via constitutive GATA-1 binding site at À373. In patients with G/A SNP at À235, GATA-1 not only binds the constitutive binding site at À373, but also the alternative binding site at À235 close to Sp1 one, leading to an increased survivin expression.
GATA-1-binding sites in survivin promoter R Boidot et al sections were incubated overnight at 4 1C with rabbit polyclonal anti-GATA-1 antibody (Abcam) diluted at 1/100 in PBS Tween 0.1%/BSA1%. The next day, sections were washed three times with PBS Tween 0.1% for 5 min each and labelled with HRP-coupled goat anti-Rabbit IgG H þ L antibody (Abcam) for 1 h at room temperature. Then, sections were washed three times with PBS for 5 min each and revelation was carried out with AEC (Dako) for 5 min at room temperature in the dark, and washed three times with PBS for 5 min each. Sections were counterstained with hematoxylin during few seconds, washed with water and mounted for microscopic observations.
cDNA synthesis and real-time quantitative RT-PCR cDNA synthesis and quantitative RT-PCR were performed as described previously (8). For GATA-1 quantification, 1.25 ml of GATA-1 Taqman Gene Expression Assay (Applied Biosystems, Foster City, CA, USA) was used with the same previous conditions.
Survivin promoter analysis for polymorphisms
A region of 500 bp (from À500 bp to þ 1 bp) upstream the survivin translation start site was analysed as described previously (Boidot et al., 2008) .
Plasmid construction and mutagenesis
The full-length of GATA-1-coding sequence was obtained using SuperScript One-Step long templates RT-PCR (Invitrogen) with 1.25 mg of total RNA from the CCRF-CEM cell line with specific primers (Supplementary Table S1 Table S1 ) and automatic sequencing. Constitutively active GATA-1 mutants were generated with GeneTailor Site-Directed Mutagenesis System (Invitrogen) by following the manufacturer's instructions. The mutations of GATA-1 plasmids were tested by PCR with specific primers (Supplementary Table S1 ) and automatic sequencing.
Chromatin immunoprecipitation and immunoprecipitated DNA PCR CCRF-CEM and MCF-7 cell lines were transiently transfected with different plasmids. In CCRF-CEM, CMV promoter was stimulated by addition of 50 ng/ml PMA and 5 mg/ml PHA. A 1/10th volume of cross-linking mix (11% Formaldehyde, 100 mM NaCl, 0.5 mM EGTA, 50 mM HEPES pH8.0) was added directly to the growth medium with rotation for 10 min at room temperature. The reaction was quenched by the addition of 125 mM of glycine. After washing twice with PBS, 750 ml of lyses buffer (1% SDS, 10 mM EDTA pH8.0, 50 mM Tris-HCl pH8.0, protease inhibitors) were added to each plate and incubated at 4 1C for 5 min. The cell lysates were sonicated one to three times for 10 s at an output of 20%. The efficiency of sonication was checked on agarose gel stained with Sybr Safe (Invitrogen) after RNaseA and proteinase K treatment (Supplementary Figures S1A and B) . The quantity of DNA was assessed using a NanoDrop 1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). Only lysates with 500-1000 bp length DNA and equal DNA quantity were used for immunoprecipitation. After centrifugation, 400 mg of lysates were diluted to a final volume of 4 ml in a mixture of nine parts dilution buffer (1% Triton X-100, 150 mM NaCl, 2 mM EDTA pH8.0, 20 mM Tris-HCl pH8.0, protease inhibitors) and 1 part lyses buffer. After addition of 4 mg of GFP antibody (Abcam), the reaction was incubated overnight at 4 1C. Simultaneously, protein A/G plus agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were pre-absorbed with 100 mg/ml of BSA and 1 mg/ml of sheared salmon sperm DNA (Invitrogen) and rotated overnight at 4 1C. Controls included no antibody (only beads) or anti-IgG antibody (Abcam) for each condition. After incubation, 20 ml of pre-absorbed beads were added to each tube and the mixture was incubated 1 h at 4 1C. The immune-complexes were collected by centrifugation, washed three times with 1 ml wash buffer (1% Triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM EDTA pH8.0, 20 mM Tris-HCl pH8.0, protease inhibitors), twice with 1 ml final wash buffer (1% Triton X-100, 0.1% SDS, 500 mM NaCl, 2 mM EDTA pH8.0, 20 mM Tris-HCl pH8.0, protease inhibitors) and eluted with 450 ml of elution buffer (1% SDS, 100 mM NaHCO 3 ). This solution was treated with RNaseA and proteinase K. Simultaneously, 40 ml of total lysates were used as an input sample and treated identically. The immunoprecipitated DNA was extracted with QIAquick PCR purification Kit (Qiagen, Courtaboeuf, France). PCR amplification for survivin promoter around À235 site was performed with immunoprecipitated DNA in 50 ml mixture containing 1 U of Taq polymerase with high fidelity and specificity for a GC-rich region (Roche, Basel, Switzerland), 300 mM dNTP and 0.5 mM of primers (Supplementary  Table S1 ). After an initial activation of enzymes for 3 min at 95 1C, PCR was followed by 35 cycles of denaturation at 95 1C for 45 s, annealing at 60 1C for 45 s, extension at 72 1C for 45 s and a final extension at 72 1C for 10 min. Quantification of DNA obtained after PCR amplification was performed with Image J software.
Downregulation of GATA-1 by siRNA transfection For siRNA efficiency, CCRF-CEM cells plated in a P60 petri dish were transfected with 400 pmol (Supplementary Table S1 ) of Stealth GATA-1 siRNA or scramble Stealth siRNA (Invitrogen) by using lipofectamine 2000 reagent. Cells were harvested at 0, 24, 48 and 72 h. Cell pellets were extracted with Trizol reagent and real-time quantitative PCR was performed for the siRNA extinction efficiency. MDA-MB-231 cells were transfected in P60 petri dishes with 400 pmol of GATA-1 or scramble siRNA. Cells were harvested at 0, 24, 48 and 72 h after transfection and cell proliferation was assessed by cell counting.
Statistical analysis
Statistical analysis was performed with Statview 5 software. Polymorphisms were correlated with survivin transcript expression using Mann-Whitney or Kruskal-Wallis test, and correlations were analysed with a z-test. Statistical significance of survivin upregulation after transfection was checked with Student's t-test. Only tests with Po0.05 were considered significant.
